Viridian Therapeutics to Participate in Upcoming June Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that members of its management team will participate in the following upcoming investor conferences:
Jefferies Global Healthcare Conference (New York, NY): Presentation on Wednesday, June 4, at 7:35am ET
Goldman Sachs 46th Annual Global Healthcare Conference 2025 (Miami, FL): Presentation on Monday, June 9, 2025 at 8:40am ET
A live webcast of each presentation can be accessed under 'Events and Presentations' on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcasts will be available following the completion of the event.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on discovering, developing and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian's expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy and safety in patients with active and chronic TED. Both THRIVE and THRIVE-2 reported positive topline data, meeting all the primary and secondary endpoints of each study. Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients with active and chronic TED.
In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Morgan Stanley Sticks to Their Buy Rating for Akeso, Inc. (9926)
In a report released yesterday, Jack Lin from Morgan Stanley maintained a Buy rating on Akeso, Inc. (9926 – Research Report), with a price target of HK$87.00. The company's shares closed yesterday at HK$83.80. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Lin is ranked #6883 out of 9552 analysts. Currently, the analyst consensus on Akeso, Inc. is a Strong Buy with an average price target of HK$103.71, a 23.76% upside from current levels. In a report released yesterday, UBS also maintained a Buy rating on the stock with a HK$112.10 price target.
Business Insider
an hour ago
- Business Insider
UBS Sticks to Their Buy Rating for Akeso, Inc. (9926)
UBS analyst Chen Chen maintained a Buy rating on Akeso, Inc. (9926 – Research Report) yesterday and set a price target of HK$112.10. The company's shares closed yesterday at HK$83.80. Confident Investing Starts Here: Chen covers the Healthcare sector, focusing on stocks such as RemeGen Co. Ltd. Class H, Hangzhou Tigermed Consulting Co., Ltd. Class H, and Akeso, Inc.. According to TipRanks, Chen has an average return of 54.7% and a 78.57% success rate on recommended stocks. Currently, the analyst consensus on Akeso, Inc. is a Strong Buy with an average price target of HK$103.71, which is a 23.76% upside from current levels. In a report released yesterday, Morgan Stanley also maintained a Buy rating on the stock with a HK$87.00 price target.
Business Insider
an hour ago
- Business Insider
Li Auto, Inc. Class A (L87) Gets a Buy from Bank of America Securities
In a report released yesterday, Ming-Hsun Lee from Bank of America Securities maintained a Buy rating on Li Auto, Inc. Class A (L87 – Research Report), with a price target of HK$125.00. The company's shares closed last Thursday at €12.32. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Lee covers the Consumer Cyclical sector, focusing on stocks such as Li Auto, XPeng, Inc. ADR, and Nio. According to TipRanks, Lee has an average return of 20.9% and a 42.05% success rate on recommended stocks. Currently, the analyst consensus on Li Auto, Inc. Class A is a Strong Buy with an average price target of €14.18, representing a 15.06% upside. In a report released yesterday, DBS also maintained a Buy rating on the stock with a HK$129.00 price target.
